Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Tofacitinib). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Tofarix 5 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Rheumatoid Arthritis: The usual dose is Tofacitinib 5 mg twice daily, or Tofacitinib 11 mg once daily. For patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is Tofacitinib 5 mg once daily. Psoriatic Arthritis (used together with nonbiologic DMARDs): The usual dose is Tofacitinib 5 mg twice daily, or Tofacitinib 11 mg once daily. For patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dose is Tofacitinib 5 mg once daily. Ulcerative Colitis: The usual dose is Tofacitinib 10 mg twice daily for at least 8 weeks, followed by 5 mg or 10 mg twice daily. If adequate therapeutic benefit is not achieved, the 10 mg twice daily dose should be discontinued after 16 weeks. The lowest effective dose should be used to maintain response.
Side Effects
The most commonly reported side effects during the first 3 months of controlled clinical trials (occurring in at least 2% of patients taking Tofatin XR alone or together with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.
Cautions & Contraindications
Warnings & Precautions
Serious Infections: Do not start Tofatin XR treatment during an active serious infection, including infections that are localized. Gastrointestinal Perforations: Use it cautiously in patients who may be at higher risk. Laboratory Monitoring: Regular lab checks are advised, since Tofatin XR can affect lymphocyte, neutrophil, hemoglobin, liver enzyme and lipid levels. Immunizations: Avoid giving live vaccines alongside Tofatin XR. Treatment should not be started if the absolute lymphocyte count is below 500 cells/mm3, the absolute neutrophil count (ANC) is below 1000 cells/mm3, or hemoglobin is below 9 gm/dL.